Treatment Information

Back

Melanoma treatment details. Biologic therapy.

Haukeland University Hospital, Bergen, Norway.

Survival: monthsCountry:Norway
Toxiciy Grade:4City/State/Province:Bergen
Treatments:Biologic therapyHospital:Haukeland University Hospital
Drugs:Journal:Link
Date:Jun 2012

Description:

Patients:
This phase 2 study involved 35 metastatic melanoma patients with a median age of 63 years; 54% were male.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab.

Toxicities:
The most severe toxicities were of grade 4 and included allergic reaction and pulmonary embolism. Grade 3 gastrointestinal disorders, heart problems, and increased blood pressure were also reported.

Results:
The median overall survival was 9 months. The median progression-free survival was 2.14 months.

Correspondence: Dr. Oddbjørn Straume; email: [email protected]



Back